Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2019 | Waldenström’s macroglobulinemia: what options are available?

Jithma Abeykoon • 3 Jun 2019
ASCO 2019
Non-Hodgkin Lymphoma Rare Diseases Waldenström’s Macroglobulinemia Bendamustine Cyclophosphamide Dexamethasone Ibrutinib Rituximab

Jithma Abeykoon, MD, PhD, of the Mayo Clinic, Rochester, MN, outlines the treatment options for patients with Waldenström’s Macroglobulinemia. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

More from Jithma Abeykoon

1:40
Rituximab combination therapy for waldenström’s macroglobulinemia
Jithma Abeykoon • 2 Jun 2019
1:21
Individualized therapy in waldenström’s macroglobulinemia
Jithma Abeykoon • 3 Jun 2019
Real world ibrutinib efficacy for Waldenström's macroglobulinemia
Jithma Abeykoon • 5 Dec 2018
Improving the accuracy of Waldenström’s prognosis
Jithma Abeykoon • 5 Dec 2018

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals